Drugs in Dev. Oncology
Phase III
India 
Dr. Reddy’s Receives Positive CHMP Opinion from EMA for its Proposed Rituximab Biosimilar
Details : Ituxredi (rituximab) is an anti-CD20 monoclonal antibody, which is indicated for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia & rheumatoid arthritis.
Product Name : Ituxredi
Product Type : Antibody
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SEC Recommends Approval to Dr Reddy's to Import and Market Anti-cancer Drug Toripalimab
Details : Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody approved in combination with cisplatin and gemcitabine for first-line treatment of metastatic or recurrent nasopharyngeal carcinoma.
Product Name : Loqtorzi
Product Type : Antibody
Upfront Cash : Inapplicable
April 18, 2024
Lead Product(s) : Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DRL_RI is being developed as a biosimilar of rituximab, CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris et...
Product Name : Ituxredi
Product Type : Antibody
Upfront Cash : Inapplicable
January 19, 2023
Details : Under the terms of this agreement, Citius will acquire Dr. Reddy's exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma from Eisai Co., Ltd.
Product Name : E7777
Product Type : Protein
Upfront Cash : $40.0 million
July 09, 2021
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CuraTeQ Biologics Receives Positive Opinion for Biosimilar Dazublys from EMA
Details : Dazublys is a trastuzumab biosimilar (HER2 inhibitor), indicated for the treatment of HER2-positive metastatic and early breast cancers.
Product Name : Dazublys
Product Type : Antibody
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.
Product Name : ZKAB001
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer.
Product Name : Triapine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lee’s 1st Patient Dosed Socazolimab, Licensed From Sorrento Treatment Cancer
Details : The initiation of this Phase 3 trial is based on the very encouraging results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage smal...
Product Name : ZKAB001
Product Type : Antibody
Upfront Cash : Inapplicable
July 23, 2021
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S FDA has granted the company Fast Track designation for irinotecan liposome injection (Onivyde) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need.
Product Name : Onivyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2020
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Agreement
Natco Pharma's Canadian Unit Signs Pact with Celgene for Cancer Treatment Drug
Details : Natco Pharma has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada.
Product Name : Lenalid
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
